Drug intelligence / Profile preview

EF-2 Peptide Vaccine

Development stage: Phase 2
Lead developer: National Cancer Institute
Modality: Peptides, Vaccines & Immunotherapeutics

Overview

EF-2 Peptide Vaccine is an immunostimulant drug initially developed by the National Cancer Institute (NCI) for the treatment of neoplasms. It is a peptide-based vaccine that utilizes peptides derived from eukaryotic elongation factor 2 (eEF2). These eEF2-derived peptides are designed to bind to human leukocyte antigen (HLA) molecules, specifically HLA-A*0201, on the surface of cancer cells. This presentation of the peptide by HLA molecules is intended to stimulate an immune response against the cancer cells. The drug has been investigated for its potential in treating various cancers, including recurrent pediatric sarcomas.

Other names: eEF2-derived peptideseEF-2-derived peptideseEF 2-derived peptides

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on EF-2 Peptide Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EF-2 Peptide Vaccine.

Explore the full profile